GlassScriptPhysician profile
Jennyfer Colls
NPI 1922670785
$696.68
in general payments reported to CMS, 2019-2025
13 companies · $375 in 2025
The $375 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $23.19 · 2023: $81.66 · 2024: $217 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $557 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $557.09 |
| Education | $116.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $194.94 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Novartis Pharmaceuticals Corporation | $100.55 | 2024-2025 | |
| Daiichi Sankyo INC. | $82.32 | 2022-2025 | Enhertu |
| Genentech USA, INC. | $68.87 | 2024-2025 | Itovebi, Phesgo |
| Astrazeneca Pharmaceuticals LP | $47.45 | 2024 | Tagrisso, Enhertu |
| Merck Sharp & Dohme LLC | $40.07 | 2024-2025 | Keytruda, Lynparza |
| Genzyme Corporation | $37.30 | 2024 | |
| Tersera Therapeutics LLC | $31.41 | 2025 | Zoladex |
| Seagen INC. | $24.79 | 2023 | Tivdak |
| Caris Mpi, INC. | $22.00 | 2025 | Mi Cancer Seek |
| Myriad Genetic Laboratories, INC. | $19.92 | 2024 | Myrisk |
| Glaxosmithkline, LLC. | $13.78 | 2025 | Jemperli, Zejula |
| Puma Biotechnology, INC. | $13.28 | 2023 | Nerlynx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennyfer Colls listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.